Roddy Hiram
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Roddy Hiram has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
Feng Xiong
Montreal Heart Institute , Montreal, Quebec
12 shared publications- Stanley Nattel
Montreal Heart Institute , Montreal, Quebec
9 shared publications - Jean-Claude Tardif
Montreal Heart Institute , Montreal, Quebec
7 shared publications Jean-François Tanguay
Montreal Heart Institute; Department of Medicine, Faculty of Medicine, Université de Montréal
6 shared publicationsPatrice Naud
Research Center, Montreal Heart Institute, Université de Montréal , 5000 Belanger Street, Montreal, Quebec H1T 1C8 , Canada
6 shared publicationsCaroline Morin
Faculty of Medicine and Health Sciences Department of Obstetrics-Gynecology Université de Sherbrooke Sherbrooke QC J1H 5N4 Canada
5 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (11) , 1231-1249
Selective blockade of microRNA-31-5p−calcitonin receptor interaction reverses established atrial fibrosis and atrial arrhythmia burden
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is promoted by atrial fibrosis, a form of structural remodelling for which effective therapies are lacking. MicroRNA-31-5p (miR-31-5p), an aging-associated, atrial-enriched microRNA, has been linked to AF, but its role in atrial fibrosis is unknown. Here we show that atrial fibroblasts from patients with persistent AF exhibit increased miR-31-5p expression and reduced expression of the calcitonin receptor (CTR, encoded by CALCR ). MiR-31-5p directly represses CTR and promotes pro-fibrotic fibroblast responses, whereas its inhibition restores CTR expression. Fibroblast-specific overexpression of miR-31 in mice reduces atrial CTR expression, increases atrial fibrosis and enhances arrhythmia susceptibility. Selective disruption of miR-31-5p− CALCR binding using a locked nucleic acid target site blocker restores atrial CTR expression, prevents fibrosis progression and reduces arrhythmia burden. In mice with established atrial remodeling, this strategy promotes fibrosis regression, identifying the miR-31-5p−CTR axis as a potential therapeutic target in AF.
- 30 October 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (11) , 1231-1249
Open AccessSelective blockade of microRNA-31-5p−calcitonin receptor interaction reverses established atrial fibrosis and atrial arrhythmia burden
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is promoted by atrial fibrosis, a form of structural remodelling for which effective therapies are lacking. MicroRNA-31-5p (miR-31-5p), an aging-associated, atrial-enriched microRNA, has been linked to AF, but its role in atrial fibrosis is unknown. Here we show that atrial fibroblasts from patients with persistent AF exhibit increased miR-31-5p expression and reduced expression of the calcitonin receptor (CTR, encoded by CALCR ). MiR-31-5p directly represses CTR and promotes pro-fibrotic fibroblast responses, whereas its inhibition restores CTR expression. Fibroblast-specific overexpression of miR-31 in mice reduces atrial CTR expression, increases atrial fibrosis and enhances arrhythmia susceptibility. Selective disruption of miR-31-5p− CALCR binding using a locked nucleic acid target site blocker restores atrial CTR expression, prevents fibrosis progression and reduces arrhythmia burden. In mice with established atrial remodeling, this strategy promotes fibrosis regression, identifying the miR-31-5p−CTR axis as a potential therapeutic target in AF.
- Open Access
- 11 September 2026
- Published by Oxford University Press (OUP) in EP Europace
Colchicine initiated before radiofrequency-induced injury attenuates left atrial inflammation, fibrosis, and susceptibility for atrial fibrillation
Background: Atrial fibrillation (AF) is the most frequently diagnosed cardiac arrhythmia. Catheter ablation using radiofrequency cauterization (CA-RFC) performed in the left atrium (LA) aims to isolate electrical sources of AF. This intervention is accompanied by frequent AF recurrences affecting 10% of patients at 30 days and 50% at one-year post-procedure. It has been suggested that inflammation could contribute to AF-recurrence post-CA-RFC. Given its anti-inflammatory and cardioprotective properties, colchicine has been proposed as a potential treatment to prevent AF recurrence post-CA-RFC. Hypothesis: RFC can lead to atrial fibrosis, inflammation, and new onset AF, which may be mitigated by colchicine. Methods: Male and female Wistar rats (225-275g) were divided into four groups: Sham or RFC, with or without colchicine (0.25 mg/kg/8h, intraperitoneally) starting 8 hours before surgery until D1 post-procedure. Sham animals underwent surgery without RFC. Electrophysiology and echocardiography assessments were performed on days 1 (D1) and 3 (D3) post-RFC. Results: Colchicine significantly lowered RFC-induced AF vulnerability, improved LA conduction velocity, reduced LA fibrosis, and attenuated LA inflammation post-procedure. Colchicine also prevented RFC-induced CD11c+ macrophages while promoting CD206+ recruitment in the LA. Conclusion: Colchicine started before RFC may be an innovative strategy to prevent the development of LA arrhythmogenic substrate post-procedure.
- 11 September 2026
- Published by Oxford University Press (OUP) in EP Europace
Open AccessColchicine initiated before radiofrequency-induced injury attenuates left atrial inflammation, fibrosis, and susceptibility for atrial fibrillation
Background: Atrial fibrillation (AF) is the most frequently diagnosed cardiac arrhythmia. Catheter ablation using radiofrequency cauterization (CA-RFC) performed in the left atrium (LA) aims to isolate electrical sources of AF. This intervention is accompanied by frequent AF recurrences affecting 10% of patients at 30 days and 50% at one-year post-procedure. It has been suggested that inflammation could contribute to AF-recurrence post-CA-RFC. Given its anti-inflammatory and cardioprotective properties, colchicine has been proposed as a potential treatment to prevent AF recurrence post-CA-RFC. Hypothesis: RFC can lead to atrial fibrosis, inflammation, and new onset AF, which may be mitigated by colchicine. Methods: Male and female Wistar rats (225-275g) were divided into four groups: Sham or RFC, with or without colchicine (0.25 mg/kg/8h, intraperitoneally) starting 8 hours before surgery until D1 post-procedure. Sham animals underwent surgery without RFC. Electrophysiology and echocardiography assessments were performed on days 1 (D1) and 3 (D3) post-RFC. Results: Colchicine significantly lowered RFC-induced AF vulnerability, improved LA conduction velocity, reduced LA fibrosis, and attenuated LA inflammation post-procedure. Colchicine also prevented RFC-induced CD11c+ macrophages while promoting CD206+ recruitment in the LA. Conclusion: Colchicine started before RFC may be an innovative strategy to prevent the development of LA arrhythmogenic substrate post-procedure.
- Open Access
- 31 July 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 202, 119824
Translational consistency of gene therapy strategies targeting inflammation in atrial fibrillation’s management
- 31 July 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 202, 119824
Open AccessTranslational consistency of gene therapy strategies targeting inflammation in atrial fibrillation’s management
- Open Access
- 20 July 2026
- Published by Elsevier in Ageing Research Reviews
- Vol. 121
Usefulness of healthy aging models to study novel prevention strategies in the treatment of cardiac inflammation and atrial fibrillation: A narrative review
- 20 July 2026
- Published by Elsevier in Ageing Research Reviews
- Vol. 121
Open AccessUsefulness of healthy aging models to study novel prevention strategies in the treatment of cardiac inflammation and atrial fibrillation: A narrative review
- Open Access
Per- and Polyfluoroalkyl Substances (PFAS) Within the Exposome: Cellular and Molecular Mechanisms Underlying a Potential Risk for Cardiac Arrhythmias and Atrial Fibrillation?
Background: Per- and polyfluoroalkyl substances (PFAS) represent a large class of synthetic fluorinated compounds characterized by highly stable carbon–fluorine bonds that confer exceptional environmental persistence and bioaccumulative properties. Although regulatory measures have restricted the production of several PFAS, including perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS), their environmental persistence continues to maintain widespread human exposure, while newly introduced replacement compounds raise additional toxicological concerns. Notably, the recent evidence demonstrating PFAS-induced alterations in key cardiac ion channel activity and electrocardiographic parameters suggest potential electrophysiological mechanisms that may contribute to arrhythmogenesis and cardiac arrhythmias including the most frequent one, atrial fibrillation (AF). Methods: We conducted a narrative literature review of experimental, epidemiological, and mechanistic studies investigating and reporting the cardiovascular, electrophysiological, and potential arrhythmogenic effects of PFAS. Results: Available evidence indicates that PFAS exposure is associated with alterations in cardiac electrophysiology, including modulation of ion channel activity (notably sodium, calcium, and potassium channels), disruption of calcium handling, and changes in electrocardiographic parameters such as QT interval prolongation, which are key contributors to arrhythmogenesis and AF. Conclusions: This review highlights the need for improved understanding of PFAS-induced electrophysiological alterations, to clarify the role of PFAS in cardiac arrhythmias including AF.
Open AccessPer- and Polyfluoroalkyl Substances (PFAS) Within the Exposome: Cellular and Molecular Mechanisms Underlying a Potential Risk for Cardiac Arrhythmias and Atrial Fibrillation?
Background: Per- and polyfluoroalkyl substances (PFAS) represent a large class of synthetic fluorinated compounds characterized by highly stable carbon–fluorine bonds that confer exceptional environmental persistence and bioaccumulative properties. Although regulatory measures have restricted the production of several PFAS, including perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS), their environmental persistence continues to maintain widespread human exposure, while newly introduced replacement compounds raise additional toxicological concerns. Notably, the recent evidence demonstrating PFAS-induced alterations in key cardiac ion channel activity and electrocardiographic parameters suggest potential electrophysiological mechanisms that may contribute to arrhythmogenesis and cardiac arrhythmias including the most frequent one, atrial fibrillation (AF). Methods: We conducted a narrative literature review of experimental, epidemiological, and mechanistic studies investigating and reporting the cardiovascular, electrophysiological, and potential arrhythmogenic effects of PFAS. Results: Available evidence indicates that PFAS exposure is associated with alterations in cardiac electrophysiology, including modulation of ion channel activity (notably sodium, calcium, and potassium channels), disruption of calcium handling, and changes in electrocardiographic parameters such as QT interval prolongation, which are key contributors to arrhythmogenesis and AF. Conclusions: This review highlights the need for improved understanding of PFAS-induced electrophysiological alterations, to clarify the role of PFAS in cardiac arrhythmias including AF.
- Open Access
- 1 February 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (2) , 216
Pro- and Anti-Inflammatory Cytokines’ Implication in Right Heart Disease, Arrhythmogenesis, and Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia responsible for increased risk of a stroke and sudden death. Right heart disease (RHD), characterized by myocardial dysfunction and structural alteration affecting the right ventricle and the right atrium, is recognized as an important risk factor for AF. Inflammation and cardiac fibrosis emerge as arrhythmogenic pathophysiological events commonly occurring in most diseases responsible for cardiac arrhythmias and AF. However, no commercially available anti-inflammatory drugs were shown to irreversibly cure AF. Hence, more investigations are required to identify the key inflammatory and fibrosis agents involved in arrhythmogenesis. In this review, we explore (i) the recent evidence of myocardial, and especially atrial, inflammation in RHD, and (ii) the relevance of targeting inflammatory and anti-inflammatory cytokines in future strategies, combined with current AF management, in RHD.
- 1 February 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (2) , 216
Open AccessPro- and Anti-Inflammatory Cytokines’ Implication in Right Heart Disease, Arrhythmogenesis, and Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia responsible for increased risk of a stroke and sudden death. Right heart disease (RHD), characterized by myocardial dysfunction and structural alteration affecting the right ventricle and the right atrium, is recognized as an important risk factor for AF. Inflammation and cardiac fibrosis emerge as arrhythmogenic pathophysiological events commonly occurring in most diseases responsible for cardiac arrhythmias and AF. However, no commercially available anti-inflammatory drugs were shown to irreversibly cure AF. Hence, more investigations are required to identify the key inflammatory and fibrosis agents involved in arrhythmogenesis. In this review, we explore (i) the recent evidence of myocardial, and especially atrial, inflammation in RHD, and (ii) the relevance of targeting inflammatory and anti-inflammatory cytokines in future strategies, combined with current AF management, in RHD.
- Open Access
- 7 January 2026
- Published by Springer Nature in Research Square
Selective blockade of microRNA-31-5p/calcitonin receptor interaction reverses established atrial fibrosis and atrial arrhythmia substrate
Atrial fibrillation (AF), the commonest cardiac arrhythmia, is a major contributor to mortality and morbidity. Atrial tissue fibrosis, a hallmark of structural remodelling in AF, is currently incurable and significantly hinders AF-treatment. MicroRNA(miR)-31 is linked to ageing (a key risk factor for AF). Here, we show that AF-patients are characterised by upregulation of miR-31-5p in atrial cardiofibroblasts that negatively regulates the calcitonin receptor (CTR), thereby promoting atrial fibrogenesis and arrhythmia. Specific blockade of miR-31-5p/CTR-mRNA binding with LNA-miRNA-Target-Site-Blocker selectively increases atrial CTR expression and reverses advanced atrial fibrosis and arrhythmogenesis in vivo. These findings suggest a key role for miR-31-5p/CTR binding in promoting atrial fibrosis and arrhythmogenesis, and represents a first example of an RNA-based therapeutic capable of reversing established fibrosis that forms an AF substrate. *Jasha Trompf, Kathryn Cox, and Mohit Hulsurkar contributed equally to this work.
- 7 January 2026
- Published by Springer Nature in Research Square
Open AccessSelective blockade of microRNA-31-5p/calcitonin receptor interaction reverses established atrial fibrosis and atrial arrhythmia substrate
Atrial fibrillation (AF), the commonest cardiac arrhythmia, is a major contributor to mortality and morbidity. Atrial tissue fibrosis, a hallmark of structural remodelling in AF, is currently incurable and significantly hinders AF-treatment. MicroRNA(miR)-31 is linked to ageing (a key risk factor for AF). Here, we show that AF-patients are characterised by upregulation of miR-31-5p in atrial cardiofibroblasts that negatively regulates the calcitonin receptor (CTR), thereby promoting atrial fibrogenesis and arrhythmia. Specific blockade of miR-31-5p/CTR-mRNA binding with LNA-miRNA-Target-Site-Blocker selectively increases atrial CTR expression and reverses advanced atrial fibrosis and arrhythmogenesis in vivo. These findings suggest a key role for miR-31-5p/CTR binding in promoting atrial fibrosis and arrhythmogenesis, and represents a first example of an RNA-based therapeutic capable of reversing established fibrosis that forms an AF substrate. *Jasha Trompf, Kathryn Cox, and Mohit Hulsurkar contributed equally to this work.
- Open Access
- 29 March 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (4) , 414
Relevance of Targeting Oxidative Stress, Inflammatory, and Pro-Resolution Mechanisms in the Prevention and Management of Postoperative Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia. AF can lead to severe complications, including stroke, myocardial infarction, and sudden death. AF risk factors include pathological aging and conditions such as obesity, diabetes, and hypertension. Clinical data revealed that cardiothoracic and non-cardiothoracic surgeries are also important risk factors for AF. Post-operative AF (POAF) is associated with important public health costs caused by increased hospitalization, frequent emergency room visits, and enhanced healthcare utilization, which altogether lead to a low quality of life for the patients. Hence, POAF is a major clinical challenge, and there is an urgent need for the development of novel therapeutic strategies. Interestingly, evidence from clinical and fundamental research converges to identify cardiac oxidative stress and atrial inflammation as the common denominators of all AF risk factors. Unresolved inflammation is suspected to provoke cardiac fibrosis, which is an important contributor to cardiac arrhythmias and AF. Antioxidant, anti-inflammatory, and pro-resolution strategies may help to combat post-operative cardiac remodeling and POAF. This article aims to review the current scientific evidence supporting the role of inflammation in the pathogenesis of POAF and explore potential novel therapeutic strategies to prevent and mitigate inflammation in the management of AF.
- 29 March 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (4) , 414
Open AccessRelevance of Targeting Oxidative Stress, Inflammatory, and Pro-Resolution Mechanisms in the Prevention and Management of Postoperative Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia. AF can lead to severe complications, including stroke, myocardial infarction, and sudden death. AF risk factors include pathological aging and conditions such as obesity, diabetes, and hypertension. Clinical data revealed that cardiothoracic and non-cardiothoracic surgeries are also important risk factors for AF. Post-operative AF (POAF) is associated with important public health costs caused by increased hospitalization, frequent emergency room visits, and enhanced healthcare utilization, which altogether lead to a low quality of life for the patients. Hence, POAF is a major clinical challenge, and there is an urgent need for the development of novel therapeutic strategies. Interestingly, evidence from clinical and fundamental research converges to identify cardiac oxidative stress and atrial inflammation as the common denominators of all AF risk factors. Unresolved inflammation is suspected to provoke cardiac fibrosis, which is an important contributor to cardiac arrhythmias and AF. Antioxidant, anti-inflammatory, and pro-resolution strategies may help to combat post-operative cardiac remodeling and POAF. This article aims to review the current scientific evidence supporting the role of inflammation in the pathogenesis of POAF and explore potential novel therapeutic strategies to prevent and mitigate inflammation in the management of AF.